Category:
Prophylactic Biological Products
CAS NO:
NA
Standard:
In-house Standards,
This combination refers to the co-formulation of Finasteride (CAS 98016-85-4) and Tadalafil (CAS 171596-29-5). The synthesis involves distinct pharmaceutical processes: Finasteride is produced via selective 5-alpha-reductase inhibition pathways, while Tadalafil utilizes a dihydropyrimidine scaffold. Both active ingredients are characterized by high purity requirements for B2B supply.
Contraindicated in women and children due to teratogenic risks. Storage requires controlled room temperature away from moisture. Strict adherence to dosage guidelines is mandatory to prevent cardiovascular adverse events associated with PDE5 inhibitors.